Incorporating economies of scale in the cost estimation in economic evaluation of PCV and HPV vaccination programmes in the Philippines: a game changer?

Table 9 Incremental cost-effectiveness ratio of HPV vaccination plus cervical cancer screening compared to cervical cancer screening alone: Incremental cost-effectiveness ratio of HPV vaccination without taking into account economies of scale and cervical cancer screening with applying economies of scale

ICER (USD/QALY)	Percent coverage of screening (with EoS approach)
Percent coverage of HPV vaccine (not taking into account EoS approach)		10	20	30	40	50	60	70	80	90	100
	10	− 30^a	120^b	280^b	440^b	600^b	770^b	950^b	1120^b	1300^b	1480^b
	20	− 30^a	120^b	280^b	440^b	600^b	770^b	950^b	1120^b	1300^b	1480^b
	30	− 30^a	120^b	280^b	440^b	600^b	770^b	950^b	1120^b	1300^b	1480^b
	40	− 30^a	120^b	280^b	440^b	600^b	770^b	950^b	1120^b	1300^b	1480^b
	50	− 30^a	120^b	280^b	440^b	600^b	770^b	950^b	1120^b	1300^b	1480^b
	60	− 30^a	120^b	280^b	440^b	600^b	770^b	950^b	1120^b	1300^b	1480^b
	70	− 30^a	120^b	280^b	440^b	600^b	770^b	950^b	1120^b	1300^b	1480^b
	80	− 30^a	120^b	280^b	440^b	600^b	770^b	950^b	1120^b	1300^b	1480^b
	90	− 30^a	120^b	280^b	440^b	600^b	770^b	950^b	1120^b	1300^b	1480^b
	100	− 30^a	120^b	280^b	440^b	600^b	770^b	950^b	1120^b	1300^b	1480^b

ICER incremental cost-effectiveness ratio, EoS economies of scale, HPV human papillomavirus vaccine
^aCost-effective
^bCost-ineffective

ISSN: 1478-7547